



MALARIA CONTROL POLICY STATEMENT

Delattre Bezons Nigeria Limited (DBN) is committed to protecting the health and safety of its employees and business partners. We recognise that within Nigeria, our operations take place in a Malaria endemic zone with a high transmission rate for Falciparum Malaria. We recognise the personal, social and economic burden of Malaria throughout the region. Our Malaria Control Policy has been formulated to minimize the risks of Malaria infection of all personnel, semi and non-immune alike, living in or visiting our facilities and operational locations.

Our programme is based on the following ABCDE principles:

A. Awareness

Improving awareness of malaria risks and prevention strategies among all risk populations including:

- Travel advice for all staff, dependants and visitors entering malaria endemic operational areas.
- Travel advice for all staff, dependants and visitors travelling to non-malaria endemic zones, where malaria awareness may be reduced. The Company will provide appropriate information reminding the traveller and their health service provider overseas of the continued risk of malaria.
- The Company will require all Subcontractors and Recruitment Agencies to include a comprehensive malaria briefing for all staff and dependants prior to transfer to malaria – endemic company locations.
- Annual malaria awareness education to all non-immune and semi-immune employees at malaria endemic locations.

B. Bite Prevention

Reducing Mosquito activity through measures including:

- Educational awareness and promotion of personal protective measures to avoid mosquito bites.
- Provision of DEET Insect Repellent to those workers (semi + non-immune) whose duties expose them to mosquito activity.
- Vector Control using a combination of recommended strategies which may include:
 - i. Eradication of areas of stagnant water
 - ii. Use of Mosquito Larvicultural agents
 - iii. Fogging in operational / residential areas were indicated

C. Chemoprophylaxis

All non-immunes (and in certain limited cases semi-immunes returning from a non-malaria endemic zone after a lengthy period) are strongly advised to take appropriate anti-malarial chemoprophylaxis. The advice will reflect current international travel advice and reflect expert opinion on the chemoprophylactic agents suitable for our geographical locations.

D. Diagnosis

The Company will provide information and resources to ensure easy access to rapid and accurate testing for malaria at operational areas. In addition, all nominated Retainer Hospitals will be audited to ensure that adequate, accurate and timely diagnostic facilities are available to all.

E. Early Treatment

The Company's medical facilities will ensure that all who are diagnosed with malaria are treated promptly and with suitable therapeutic agents. We will also ensure that our Retainer Hospitals provide prompt and appropriate treatment for eligible staff and dependants.

We expect all associated Subcontractors to adopt similar strategies, which will be the subject of audit both by the Company and expert independent review.

Responsibilities

All employees are personally responsible for compliance with this policy to ensure their good health and well being.

Segun EZEKIEL
Deputy Managing Director
January 2025